Advertisement

Five common errors to avoid in clinical practice: the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) Choosing Wisely Campaign

  • Elisa StasiEmail author
  • Andrea Michielan
  • Gaetano Cristian Morreale
  • Alessandro Tozzi
  • Ludovica Venezia
  • Francesco Bortoluzzi
  • Omero Triossi
  • Marco Soncini
  • Gioacchino Leandro
  • Giuseppe Milazzo
  • Andrea Anderloni
CE - ORIGINAL
  • 55 Downloads

Abstract

Modern medicine provides almost infinite diagnostic and therapeutic possibilities if compared to the past. As a result, patients undergo a multiplication of tests and therapies, which in turn may trigger further tests, often based on physicians’ attitudes or beliefs, which are not always evidence-based. The Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) adhered to the Choosing Wisely Campaign to promote an informed, evidence-based approach to gastroenterological problems. The aim of this article is to report the five recommendations of the AIGO Choosing Wisely Campaign, and the process used to develop them. The AIGO members’ suggestions regarding inappropriate practices/interventions were collected. One hundred and twenty-one items were identified. Among these, five items were selected and five recommendations were developed. The five recommendations developed were: (1) Do not request a fecal occult blood test outside the colorectal cancer screening programme; (2) Do not repeat surveillance colonoscopy for polyps, after a quality colonoscopy, before the interval suggested by the gastroenterologist on the colonoscopy report, or based on the polyp histology report; (3) Do not repeat esophagogastroduodenoscopy in patients with reflux symptoms, with or without hiatal hernia, in the absence of different symptoms or alarm symptoms; (4) Do not repeat abdominal ultrasound in asymptomatic patients with small hepatic haemangiomas (diameter < 3 cm) once the diagnosis has been established conclusively; (5) Do not routinely prescribe proton pump inhibitors within the context of steroid use or long-term in patients with functional dyspepsia. AIGO adhered to the Choosing Wisely Campaign and developed five recommendations. Further studies are needed to assess the impact of these recommendations in clinical practice with regards to clinical outcome and cost-effectiveness.

Keywords

Appropriateness Choosing wisely Overdiagnosis Overtreatment Recommendations 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statement of human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

None.

References

  1. 1.
    O’Sullivan JW, Muntinga T, Grigg S, Ioannidis JPA (2018) Prevalence and outcomes of incidental imaging findings: umbrella review. BMJ 18(361):k2387CrossRefGoogle Scholar
  2. 2.
    Deyo RA (2002) Cascade effects of medical technology. Annu Rev Public Health 23:23–44CrossRefGoogle Scholar
  3. 3.
    Wolfson D, Santa J, Slass L (2014) Engaging physicians and consumers in conversations about treatment overuse and waste: a short history of the choosing wisely campaign. Acad Med 89(7):990–995CrossRefGoogle Scholar
  4. 4.
    Montano N, Costantino G, Casazza G et al (2016) The Italian Society of Internal Medicine choosing wisely campaign. Intern Emerg Med 11(8):1125–1130CrossRefGoogle Scholar
  5. 5.
    Hillis CM, Schimmer AD, Couban S et al (2015) The Canadian Choosing Wisely campaign: the Canadian Hematology Society’s top five tests and treatments. Ann Hematol 94(4):541–545CrossRefGoogle Scholar
  6. 6.
    Ho T, Dukhovny D, Zupancic JA et al (2015) Choosing wisely in newborn medicine: five opportunities to increase value. Pediatrics 136(2):e482–e489CrossRefGoogle Scholar
  7. 7.
    Hahn C, Kavanagh B, Bhatnagar A et al (2014) Choosing wisely: the American Society for Radiation Oncology’s top 5 list. Pract. Radiat Oncol 4(6):349–355Google Scholar
  8. 8.
    Bulger J, Nickel W, Messler J et al (2013) Choosing wisely in adult hospital medicine: five opportunities for improved healthcare value. J Hosp Med 8(9):486–492CrossRefGoogle Scholar
  9. 9.
    Loder E, Weizenbaum E, Frishberg B et al (2013) Choosing wisely in headache medicine: the American Headache Society’s list of five things physicians and patients should question. Headache. 53(10):1651–1659CrossRefGoogle Scholar
  10. 10.
    Hicks LK, Bering H, Carson KR et al (2013) The ASH Choosing Wisely® campaign: five hematologic tests and treatments to question. Blood 122(24):3879–3883CrossRefGoogle Scholar
  11. 11.
    Mitera G, Earle C, Latosinsky S et al (2015) Choosing Wisely Canada cancer list: ten low-value or harmful practices that should be avoided in cancer care. J Oncol Pract. 11(3):e296–e303CrossRefGoogle Scholar
  12. 12.
    Wiener RS, Ouellette DR, Diamond E et al (2014) An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine. Chest 145(6):1383–1391CrossRefGoogle Scholar
  13. 13.
    Nguyen GC, Boland K, Afif W et al (2017) Modified Delphi process for the development of choosing wisely for inflammatory bowel disease. Inflamm Bowel Dis 23(6):858–865CrossRefGoogle Scholar
  14. 14.
    Winawer S, Fletcher R, Rex D et al (2003) Gastrointestinal consortium panel. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology 124(2):544–560CrossRefGoogle Scholar
  15. 15.
    Knudsen AB, Zauber AG, Rutter CM et al (2016) Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US preventive services task force. JAMA 315(23):2595–2609CrossRefGoogle Scholar
  16. 16.
    Fisher DA, Judd L, Sanford NS (2005) Inappropriate colorectal cancer screening: findings and implications. Am J Gastroenterol 100(11):2526–2530CrossRefGoogle Scholar
  17. 17.
    Powell AA, Saini SD, Breitenstein MK et al (2015) Rates and correlates of potentially inappropriate colorectal cancer screening in the veterans health administration. J Gen Intern Med 30(6):732–741CrossRefGoogle Scholar
  18. 18.
    Friedman A, Chan A, Chin LC et al (2010) Use and abuse of faecal occult blood tests in an acute hospital inpatient setting. Intern Med J 40(2):107–111CrossRefGoogle Scholar
  19. 19.
    Narula N, Ulic D, Al-Dabbagh R et al (2014) Fecal occult blood testing as a diagnostic test in symptomatic patients is not useful: a retrospective chart review. Can J Gastroenterol Hepatol. 28(8):421–426CrossRefGoogle Scholar
  20. 20.
    Rao SK, Schilling TF, Sequist TD (2009) Challenges in the management of positive fecal occult blood tests. J Gen Intern Med 24(3):356–360CrossRefGoogle Scholar
  21. 21.
    Mosadeghi S, Ren H, Catungal J et al (2016) Utilization of fecal occult blood test in the acute hospital setting and its impact on clinical management and outcomes. J Postgrad Med 62(2):91–95CrossRefGoogle Scholar
  22. 22.
    van Rijn AF, Stroobants AK, Deutekom M et al (2012) Inappropriate use of the faecal occult blood test in a University Hospital in the Netherlands. Eur J Gastroenterol Hepatol 24(11):1266–1269CrossRefGoogle Scholar
  23. 23.
    Winawer SJ, Zauber AG, Ho MN et al (1993) Prevention of colorectal cancer by colonoscopic polypectomy. The national polyp study workgroup. N Engl J Med 329(27):1977–1981CrossRefGoogle Scholar
  24. 24.
    Cottet V, Jooste V, Fournel I et al (2012) Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. Gut 61(8):1180–1186CrossRefGoogle Scholar
  25. 25.
    Brenner H, Chang-Claude J, Rickert A et al (2012) Risk of colorectal cancer after detection and removal of adenomas at colonoscopy: population-based case-control study. J Clin Oncol 30(24):2969–2976CrossRefGoogle Scholar
  26. 26.
    Cairns SR, Scholefield JH, Steele RJ et al (2010) British Society of Gastroenterology; Association of Coloproctology for Great Britain and Ireland. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 59(5):666–689CrossRefGoogle Scholar
  27. 27.
    Lieberman DA, Rex DK, Winawer SJ et al (2012) United States Multi-Society Task Force on Colorectal Cancer. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 143(3):844–857CrossRefGoogle Scholar
  28. 28.
    Hassan C, Quintero E, Dumonceau JM et al (2013) European Society of Gastrointestinal Endoscopy. Post-polypectomy colonoscopy surveillance: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 45(10):842–851CrossRefGoogle Scholar
  29. 29.
    Radaelli F, Paggi S, Bortoli A et al (2012) Italian Association of Hospital Gastroenterologists (AIGO). Overutilization of post-polypectomy surveillance colonoscopy in clinical practice: a prospective, multicentre study. Dig Liver Dis 44(9):748–753CrossRefGoogle Scholar
  30. 30.
    Van Heijningen EM, Lansdorp-Vogelaar I, Steyerberg EW et al (2015) Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study. Gut 64(10):1584–1592CrossRefGoogle Scholar
  31. 31.
    Anderson JC, Baron JA, Ahnen DJ et al (2017) Factors associated with shorter colonoscopy surveillance intervals for patients with low-risk colorectal adenomas and effects on outcome. Gastroenterology 152(8):1933–1943CrossRefGoogle Scholar
  32. 32.
    Van Hees F, Zauber AG, Klabunde CN et al (2014) The appropriateness of more intensive colonoscopy screening than recommended in Medicare beneficiaries: a modeling study. JAMA Intern Med. 174(10):1568–1576CrossRefGoogle Scholar
  33. 33.
    Whitlock EP, Lin JS, Liles E et al (2008) Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Int Med 149:638–658CrossRefGoogle Scholar
  34. 34.
    Warren JL, Klabunde CN, Mariotto AB et al (2009) Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med 150(849–57):W152Google Scholar
  35. 35.
    DeVault KR, Castell DO (2005) Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 100:190–200CrossRefGoogle Scholar
  36. 36.
    El-Serag HB, Sweet S, Winchester CC et al (2014) Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 63:871–880CrossRefGoogle Scholar
  37. 37.
    Kahrilas PJ, Shaheen NJ, Vaezi MF et al (2008) American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 135:1383–1391CrossRefGoogle Scholar
  38. 38.
    Vakil N, van Zanten SV, Kahrilas P et al (2006) The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101:1900–1920CrossRefGoogle Scholar
  39. 39.
    Katz PO, Gerson LB, Vela MF (2013) Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol 108:308–328CrossRefGoogle Scholar
  40. 40.
    Shaheen NJ, Weinberg DS, Denberg TD et al (2012) Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann Intern Med 157:808–816CrossRefGoogle Scholar
  41. 41.
    Vaira D, Gatta L, Ricci C et al (2011) Gastroesophageal reflux disease and Barrett’s esophagus. Intern Emerg Med 6(4):299–306CrossRefGoogle Scholar
  42. 42.
    Fock KM, Talley N, Hunt R et al (2004) Report of the Asia-Pacific consensus on the management of gastroesophageal reflux disease. J Gastroenterol Hepatol 19:357–367CrossRefGoogle Scholar
  43. 43.
    NICE Clinical guideline (2014) Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management. nice.org.uk/guidance/cg184
  44. 44.
    Takubo K, Honma N, Aryal G et al (2009) Is there a set of histologic changes that are invariably reflux associated? Arch Pathol Lab Med 129:159–163Google Scholar
  45. 45.
    Horta G, Lopez M, Dotte A et al (2015) Benign focal liver lesions detected by computed tomography: review of 1,184 examinations. Rev Med Chil 143:197–202CrossRefGoogle Scholar
  46. 46.
    Bahirwani R, Reddy KR (2008) Review article: the evaluation of solitary liver masses. Aliment Pharmacol Ther 28:953–965PubMedGoogle Scholar
  47. 47.
    Gandolfi L, Leo P, Solmi L et al (1991) Natural history of hepatic haemangiomas: clinical and ultrasound study. Gut 32(6):677–680CrossRefGoogle Scholar
  48. 48.
    Mungovan JA, Cronan JJ, Vacarro J (1994) Hepatic cavernous hemangiomas: lack of enlargement over time. Radiology 191(1):111–113CrossRefGoogle Scholar
  49. 49.
    Okano H, Shiraki K, Inoue H et al (2001) Natural course of cavernous hepatic hemangioma. Oncol Rep 8(2):411–414PubMedGoogle Scholar
  50. 50.
    Gibney RG, Hendin AP, Cooperberg PL (1987) Sonographically detected hepatic hemangiomas: absence of change over time. AJR Am J Roentgenol 149(5):953–957CrossRefGoogle Scholar
  51. 51.
    Hasan HY, Hinshaw JL, Borman EJ et al (2014) Assessing normal growth of hepatic hemangiomas during long-term follow-up. JAMA Surg. 149(12):1266–1271CrossRefGoogle Scholar
  52. 52.
    Herman P, Costa ML, Machado MA et al (2005) Management of hepatic hemangiomas: a 14-year experience. J Gastrointest Surg 9:853–859CrossRefGoogle Scholar
  53. 53.
    Clinical EASL (2016) Practice Guidelines on the management of benign liver tumours. European Association for the Study of the Liver (EASL). J Hepatol 65(2):386–398CrossRefGoogle Scholar
  54. 54.
    Scarpignato C, Gatta L, Zullo A et al (2016) Effective and safe proton pump inhibitor therapy in acid-related diseases–a position paper addressing benefits and potential harms of acid suppression. BMC Med 14:179CrossRefGoogle Scholar
  55. 55.
    Munson JC, Wahl PM, Daniel G et al (2012) Factors associated with the initiation of proton pump inhibitors in corticosteroid users. Pharmacoepidemiol Drug Saf 21:366–374CrossRefGoogle Scholar
  56. 56.
    Heidelbaugh JJ, Kim AH, Chang R et al (2012) Overutilization of proton-pump inhibitors: what the clinician needs to know. Therap Adv Gastroenterol 5:219–232CrossRefGoogle Scholar
  57. 57.
    Savarino V, Dulbecco P, De Bortoli N et al (2017) The appropriate use of proton pump inhibitors: need for a reappraisal. Eur J Internal Med 37:19–24CrossRefGoogle Scholar
  58. 58.
    Stanghellini V, Chan FKL, Hasler WL et al (2016) Gastroduodenal disorders. Gastroenterology 150:1380–1392CrossRefGoogle Scholar
  59. 59.
    Moayyedi P, Delaney BC, Vakil N et al (2004) The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 127:1329–1337CrossRefGoogle Scholar
  60. 60.
    Moayyedi P, Lacy BE, Andrews CN et al (2017) ACG and CAG clinical guideline: management of dyspepsia. Am J Gastroenterol 112:988–1013CrossRefGoogle Scholar
  61. 61.
    Levinson W, Huynh T (2014) Engaging physicians and patients in conversations about unnecessary tests and procedures: choosing wisely Canada. CMAJ 186(5):325–326CrossRefGoogle Scholar
  62. 62.
    Buscarini E, Conte D, Cannizzaro R et al (2014) White paper of Italian gastroenterology: delivery of services for digestive diseases in Italy: weaknesses and strengths. Dig Liver Dis. 46(7):579–589CrossRefGoogle Scholar
  63. 63.
    Asch DA, Nicholson S, Srinivas S et al (2009) Evaluating obstetrical residency programs using patient outcomes. JAMA 302:1277–1283CrossRefGoogle Scholar
  64. 64.
    Cardone F, Cheung D, Han A et al (2017) Choosing Wisely Canada Students and trainees advocating for resource stewardship (STARS) campaign: a descriptive evaluation. CMAJ Open. 5(4):E864–E871CrossRefGoogle Scholar
  65. 65.
    Elli L, Tenca A, Soncini M et al (2013) Defensive medicine practices among gastroenterologists in Lombardy: between lawsuits and the economic crisis. Dig Liver Dis. 45(6):469–473CrossRefGoogle Scholar
  66. 66.
    Hiyama T, Yoshihara M, Tanaka S et al (2006) Defensive medicine practices among gastroenterologists in Japan. World J Gastroenterol 12:7671–7675CrossRefGoogle Scholar
  67. 67.
    Kessler DP, Summerton N, Graham JR (2006) Effects of the medical liability system in Australia, the UK, and the USA. Lancet 368:240–246CrossRefGoogle Scholar
  68. 68.
    Institute of Medicine (US) (2010) Roundtable on Evidence-Based Medicine. In: Yong PL, Saunders RS, Olsen LA (eds) The healthcare imperative: lowering costs and improving outcomes: workshop series summary. National Academies Press, Washington (DC)Google Scholar
  69. 69.
    Dzau VJ, Kirch DG, Nasca TJ (2018) To care is human—collectively confronting the clinician-burnout crisis. N Engl J Med 378(4):312–314CrossRefGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna 2018

Authors and Affiliations

  • Elisa Stasi
    • 1
    Email author
  • Andrea Michielan
    • 2
  • Gaetano Cristian Morreale
    • 3
  • Alessandro Tozzi
    • 4
  • Ludovica Venezia
    • 5
  • Francesco Bortoluzzi
    • 6
  • Omero Triossi
    • 7
  • Marco Soncini
    • 8
  • Gioacchino Leandro
    • 1
  • Giuseppe Milazzo
    • 9
  • Andrea Anderloni
    • 10
  1. 1.Gastroenterology UnitNational Institute of Gastroenterology “S. De Bellis” Research HospitalCastellana GrotteItaly
  2. 2.Gastroenterology and Digestive Endoscopy UnitOspedale Santa ChiaraTrentoItaly
  3. 3.Gastroenterology UnitPalermoItaly
  4. 4.Gastroenterology UnitSan Giuseppe HospitalEmpoliItaly
  5. 5.Gastroenterology UnitAOU Città della Salute e della Scienza TurinTurinItaly
  6. 6.Gastroenterology UnitVeniceItaly
  7. 7.Gastroenterology UnitAUSL RomagnaRavennaItaly
  8. 8.Gastroenterology UnitSan Carlo Borromeo HospitalMilanItaly
  9. 9.Department of MedicineOspedale Vittorio Emanuele IIISalemiItaly
  10. 10.Digestive Endoscopy UnitHumanitas Research HospitalMilanItaly

Personalised recommendations